Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Applied filters
Content I can access

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 87-B, Issue SUPP_III | Pages 249 - 249
1 Sep 2005
Faber C Stallmann H Lyaruu D Joosten U von Eiff C van Nieuw Amerongen A Wuisman P
Full Access

Introduction: Antimicrobial peptides (AMP) are a novel class of antimicrobial agents effective against among others MRSA in vitro. Previously, we reported the release of AMP Dhvar-5 and hLF1-11 from different bone cements(1,4). In this study we investigated the efficacy of calcium phosphate cement (Calcibon®) loaded with hLF1-11 for the treatment of MRSA osteomyelitis in vivo.

Materials and Methods: Osteomyelitis was induced in 14 rabbits by MRSA, as described by Norden et al.(2) After 3 weeks all animals were treated by a thorough local debridement and subsequent filling of the tibial cavity with Calcibon® bone cement. Six control animals received Calcibon® without additives and 8 animals received Calcibon® loaded with 50 mg hLFl-11 per g cement powder. Treatment outcome was analyzed by microbiology, radiology and histology after 3 weeks follow-up.

Results: The results are shown in table 1. The number of CFU per gram of bone were significantly lower in the 50 mg hLFl-11 group (median 3.0x103 CFU/g bone) compared to the control group (median 3.5xl06 CFU/g bone).

Conclusion: This study demonstrates that hLFl-11 has the ability to cure an existing MRSA osteomyelitis in 5 out of 8 animals. The data suggest that the antimicrobial peptide, hLFl-11 in Calcibon® is able to treat osteomyelitis in vivo.